Genetic alterations of DNA methylation machinery in human diseases

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1 Smith ZD, Meissner A. DNA methylation: roles in mammalian development. Nat. Rev. Genet. 14(3), 204–220 (2013).
  Medline CASGoogle Scholar
• 2 Chen T, Li E. Establishment and maintenance of DNA methylation patterns in mammals. Curr. Top. Microbiol. Immunol. 301, 179–201 (2006).
  Medline CASGoogle Scholar
• 3 Heyn H, Esteller M. DNA methylation profiling in the clinic: applications and challenges. Nat. Rev. Genet. 13(10), 679–692 (2012).
  Medline CASGoogle Scholar
• 4 Subramaniam D, Thombre R, Dhar A, Anant S. DNA methyltransferases: a novel target for prevention and therapy. Front. Oncol. 4, 80 (2014).
  MedlineGoogle Scholar
• 5 Easwaran H, Tsai HC, Baylin SB. Cancer epigenetics: tumor heterogeneity, plasticity of stem-like states, and drug resistance. Mol. Cell 54(5), 716–727 (2014).
  Medline CASGoogle Scholar
• 6 Bourc'his D, Xu GL, Lin CS, Bollman B, Bestor TH. Dnmt3L and the establishment of maternal genomic imprints. Science 294(5551), 2536–2539 (2001).
  MedlineGoogle Scholar
• 7 Hata K, Okano M, Lei H, Li E. Dnmt3L cooperates with the Dnmt3 family of de novo DNA methyltransferases to establish maternal imprints in mice. Development 129(8), 1983–1993 (2002).
  Medline CASGoogle Scholar
• 8 Neri F, Krepelova A, Incarnato D et al. Dnmt3L antagonizes DNA methylation at bivalent promoters and favors DNA methylation at gene bodies in ESCs. Cell 155(1), 121–134 (2013).
  Medline CASGoogle Scholar
• 9 Chen T, Tsujimoto N, Li E. The PWWP domain of Dnmt3a and Dnmt3b is required for directing DNA methylation to the major satellite repeats at pericentric heterochromatin. Mol. Cell. Biol. 24(20), 9048–9058 (2004).
  Medline CASGoogle Scholar
• 10 Otani J, Nankumo T, Arita K, Inamoto S, Ariyoshi M, Shirakawa M. Structural basis for recognition of H3K4 methylation status by the DNA methyltransferase 3A ATRX-DNMT3-DNMT3L domain. EMBO Rep. 10(11), 1235–1241 (2009).
  Medline CASGoogle Scholar
• 11 Ooi SK, Qiu C, Bernstein E et al. DNMT3L connects unmethylated lysine 4 of histone H3 to de novo methylation of DNA. Nature 448(7154), 714–717 (2007).
  Medline CASGoogle Scholar
• 12 Tahiliani M, Koh KP, Shen Y et al. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science 324(5929), 930–935 (2009).•• First study showing that TET1 can convert 5-methycytosine to hydroxymethylcytosine.
  Medline CASGoogle Scholar
• 13 Pastor WA, Aravind L, Rao A. TETonic shift: biological roles of TET proteins in DNA demethylation and transcription. Nat. Rev. Mol. Cell Biol. 14(6), 341–356 (2013).
  Medline CASGoogle Scholar
• 14 Wu H, Zhang Y. Reversing DNA methylation: mechanisms, genomics, and biological functions. Cell 156(1–2), 45–68 (2014).
  Medline CASGoogle Scholar
• 15 Zhao H, Chen T. Tet family of 5-methylcytosine dioxygenases in mammalian development. J. Hum. Genet. 58(7), 421–427 (2013).
  Medline CASGoogle Scholar
• 16 Klose RJ, Bird AP. Genomic DNA methylation: the mark and its mediators. Trends Biochem. Sci. 31(2), 89–97 (2006).
  Medline CASGoogle Scholar
• 17 Filion GJ, Zhenilo S, Salozhin S, Yamada D, Prokhortchouk E, Defossez PA. A family of human zinc finger proteins that bind methylated DNA and repress transcription. Mol. Cell Biol. 26(1), 169–181 (2006).
  Medline CASGoogle Scholar
• 18 Blattler A, Yao L, Wang Y, Ye Z, Jin VX, Farnham PJ. ZBTB33 binds unmethylated regions of the genome associated with actively expressed genes. Epigenetics Chromatin 6(1), 13 (2013).
  Medline CASGoogle Scholar
• 19 Quenneville S, Verde G, Corsinotti A et al. In embryonic stem cells, ZFP57/KAP1 recognize a methylated hexanucleotide to affect chromatin and DNA methylation of imprinting control regions. Mol. Cell 44(3), 361–372 (2011).
  Medline CASGoogle Scholar
• 20 Bostick M, Kim JK, Esteve PO, Clark A, Pradhan S, Jacobsen SE. UHRF1 plays a role in maintaining DNA methylation in mammalian cells. Science 317(5845), 1760–1764 (2007).
  Medline CASGoogle Scholar
• 21 Sharif J, Muto M, Takebayashi S et al. The SRA protein Np95 mediates epigenetic inheritance by recruiting Dnmt1 to methylated DNA. Nature 450(7171), 908–912 (2007).
  Medline CASGoogle Scholar
• 22 Yildirim O, Li R, Hung JH et al. Mbd3/NURD complex regulates expression of 5-hydroxymethylcytosine marked genes in embryonic stem cells. Cell 147(7), 1498–1510 (2011).
  Medline CASGoogle Scholar
• 23 Mellen M, Ayata P, Dewell S, Kriaucionis S, Heintz N. MeCP2 binds to 5hmC enriched within active genes and accessible chromatin in the nervous system. Cell 151(7), 1417–1430 (2012).
  Medline CASGoogle Scholar
• 24 Spruijt CG, Gnerlich F, Smits AH et al. Dynamic readers for 5-(hydroxy)methylcytosine and its oxidized derivatives. Cell 152(5), 1146–1159 (2013).
  Medline CASGoogle Scholar
• 25 Klein CJ, Botuyan MV, Wu Y et al. Mutations in DNMT1 cause hereditary sensory neuropathy with dementia and hearing loss. Nat. Genet. 43(6), 595–600 (2011).
  Medline CASGoogle Scholar
• 26 Winkelmann J, Lin L, Schormair B et al. Mutations in DNMT1 cause autosomal dominant cerebellar ataxia, deafness and narcolepsy. Hum. Mol. Genet. 21(10), 2205–2210 (2012).
  Medline CASGoogle Scholar
• 27 Moghadam KK, Pizza F, La Morgia C et al. Narcolepsy is a common phenotype in HSAN IE and ADCA-DN. Brain 137(Pt 6), 1643–1655 (2014).
  MedlineGoogle Scholar
• 28 Klein CJ, Bird T, Ertekin-Taner N et al. DNMT1 mutation hot spot causes varied phenotypes of HSAN1 with dementia and hearing loss. Neurology 80(9), 824–828 (2013).
  Medline CASGoogle Scholar
• 29 Yuan J, Higuchi Y, Nagado T et al. Novel mutation in the replication focus targeting sequence domain of DNMT1 causes hereditary sensory and autonomic neuropathy IE. J. Peripher. Nerv. Syst. 18(1), 89–93 (2013).
  Medline CASGoogle Scholar
• 30 Pedroso JL, Povoas Barsottini OG, Lin L, Melberg A, Oliveira AS, Mignot E. A novel de novo exon 21 DNMT1 mutation causes cerebellar ataxia, deafness, and narcolepsy in a Brazilian patient. Sleep 36(8), 1257–1259, 1259A (2013).
  MedlineGoogle Scholar
• 31 Takeshita K, Suetake I, Yamashita E et al. Structural insight into maintenance methylation by mouse DNA methyltransferase 1 (Dnmt1). Proc. Natl Acad. Sci. USA 108(22), 9055–9059 (2011).
  Medline CASGoogle Scholar
• 32 Mastroeni D, Chouliaras L, Grover A et al. Reduced RAN expression and disrupted transport between cytoplasm and nucleus; a key event in Alzheimer's disease pathophysiology. PLoS ONE 8(1), e53349 (2013).
  Medline CASGoogle Scholar
• 33 Hutnick LK, Golshani P, Namihira M et al. DNA hypomethylation restricted to the murine forebrain induces cortical degeneration and impairs postnatal neuronal maturation. Hum. Mol. Genet. 18(15), 2875–2888 (2009).
  Medline CASGoogle Scholar
• 34 Ley TJ, Ding L, Walter MJ et al. DNMT3A mutations in acute myeloid leukemia. N. Engl. J. Med. 363(25), 2424–2433 (2010).•• First report identifying DNMT3A mutations in acute myeloid leukemia.
  Medline CASGoogle Scholar
• 35 Yamashita Y, Yuan J, Suetake I et al. Array-based genomic resequencing of human leukemia. Oncogene 29(25), 3723–3731 (2010).
  Medline CASGoogle Scholar
• 36 Yan XJ, Xu J, Gu ZH et al. Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia. Nat. Genet. 43(4), 309–315 (2011).
  Medline CASGoogle Scholar
• 37 Im AP, Sehgal AR, Carroll MP et al. DNMT3A and IDH mutations in acute myeloid leukemia and other myeloid malignancies: associations with prognosis and potential treatment strategies. Leukemia 28(9), 1774–1783 (2014).
  Medline CASGoogle Scholar
• 38 Shlush LI, Zandi S, Mitchell A et al. Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia. Nature 506(7488), 328–333 (2014).
  Medline CASGoogle Scholar
• 39 Kim SJ, Zhao H, Hardikar S, Singh AK, Goodell MA, Chen T. A DNMT3A mutation common in AML exhibits dominant-negative effects in murine ES cells. Blood 122(25), 4086–4089 (2013).
  Medline CASGoogle Scholar
• 40 Russler-Germain DA, Spencer DH, Young MA et al. The R882H DNMT3A mutation associated with AML dominantly inhibits wild-type DNMT3A by blocking its ability to form active tetramers. Cancer Cell 25(4), 442–454 (2014).
  Medline CASGoogle Scholar
• 41 Xu J, Wang YY, Dai YJ et al. DNMT3A Arg882 mutation drives chronic myelomonocytic leukemia through disturbing gene expression/DNA methylation in hematopoietic cells. Proc. Natl Acad. Sci. USA 111(7), 2620–2625 (2014).
  Medline CASGoogle Scholar
• 42 Figueroa ME, Lugthart S, Li Y et al. DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. Cancer Cell 17(1), 13–27 (2010).
  Medline CASGoogle Scholar
• 43 Challen GA, Sun D, Jeong M et al. Dnmt3a is essential for hematopoietic stem cell differentiation. Nat. Genet. 44(1), 23–31 (2012).
  CASGoogle Scholar
• 44 Tatton-Brown K, Seal S, Ruark E et al. Mutations in the DNA methyltransferase gene DNMT3A cause an overgrowth syndrome with intellectual disability. Nat. Genet. 46(4), 385–388 (2014).
  Medline CASGoogle Scholar
• 45 Okano M, Bell DW, Haber DA, Li E. DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell 99(3), 247–257 (1999).•• First report identifying DNMT3B mutations in immunodeficiency, centromeric instability and facial anomalies (ICF) syndrome.
  Medline CASGoogle Scholar
• 46 Ehrlich M, Sanchez C, Shao C et al. ICF, an immunodeficiency syndrome: DNA methyltransferase 3B involvement, chromosome anomalies, and gene dysregulation. Autoimmunity 41(4), 253–271 (2008).
  Medline CASGoogle Scholar
• 47 Hagleitner MM, Lankester A, Maraschio P et al. Clinical spectrum of immunodeficiency, centromeric instability and facial dysmorphism (ICF syndrome). J. Med. Genet. 45(2), 93–99 (2008).
  Medline CASGoogle Scholar
• 48 Xu GL, Bestor TH, Bourc'his D et al. Chromosome instability and immunodeficiency syndrome caused by mutations in a DNA methyltransferase gene. Nature 402(6758), 187–191 (1999).
  Medline CASGoogle Scholar
• 49 Hansen RS, Wijmenga C, Luo P et al. The DNMT3B DNA methyltransferase gene is mutated in the ICF immunodeficiency syndrome. Proc. Natl Acad. Sci. USA 96(25), 14412–14417 (1999).
  Medline CASGoogle Scholar
• 50 Gowher H, Jeltsch A. Molecular enzymology of the catalytic domains of the Dnmt3a and Dnmt3b DNA methyltransferases. J. Biol. Chem. 277(23), 20409–20414 (2002).
  Medline CASGoogle Scholar
• 51 Moarefi AH, Chedin F. ICF syndrome mutations cause a broad spectrum of biochemical defects in DNMT3B-mediated de novo DNA methylation. J. Mol. Biol. 409(5), 758–772 (2011).
  Medline CASGoogle Scholar
• 52 Shirohzu H, Kubota T, Kumazawa A et al. Three novel DNMT3B mutations in Japanese patients with ICF syndrome. Am. J. Med. Genet. 112(1), 31–37 (2002).
  MedlineGoogle Scholar
• 53 Qiu C, Sawada K, Zhang X, Cheng X. The PWWP domain of mammalian DNA methyltransferase Dnmt3b defines a new family of DNA-binding folds. Nat. Struct. Biol. 9(3), 217–224 (2002).
  Medline CASGoogle Scholar
• 54 De Greef JC, Wang J, Balog J et al. Mutations in ZBTB24 are associated with immunodeficiency, centromeric instability, and facial anomalies syndrome type 2. Am. J. Hum. Genet. 88(6), 796–804 (2011).• First report identifying ZBTB24 mutations in ICF type 2 patients.
  Medline CASGoogle Scholar
• 55 Chouery E, Abou-Ghoch J, Corbani S et al. A novel deletion in ZBTB24 in a Lebanese family with immunodeficiency, centromeric instability, and facial anomalies syndrome type 2. Clin. Genet. 82(5), 489–493 (2012).
  Medline CASGoogle Scholar
• 56 Cerbone M, Wang J, Van Der Maarel SM et al. Immunodeficiency, centromeric instability, facial anomalies (ICF) syndrome, due to ZBTB24 mutations, presenting with large cerebral cyst. Am. J. Med. Genet. 158A(8), 2043–2046 (2012).
  MedlineGoogle Scholar
• 57 Nitta H, Unoki M, Ichiyanagi K et al. Three novel ZBTB24 mutations identified in Japanese and Cape Verdean type 2 ICF syndrome patients. J. Hum. Genet. 58(7), 455–460 (2013).
  Medline CASGoogle Scholar
• 58 Weemaes CM, Van Tol MJ, Wang J et al. Heterogeneous clinical presentation in ICF syndrome: correlation with underlying gene defects. Eur. J. Hum. Genet. 21(11), 1219–1225 (2013).
  Medline CASGoogle Scholar
• 59 Jiang YL, Rigolet M, Bourc'his D et al. DNMT3B mutations and DNA methylation defect define two types of ICF syndrome. Hum. Mut. 25(1), 56–63 (2005).
  Medline CASGoogle Scholar
• 60 Lee SU, Maeda T. POK/ZBTB proteins: an emerging family of proteins that regulate lymphoid development and function. Immunol. Rev. 247(1), 107–119 (2012).
  MedlineGoogle Scholar
• 61 Blanco-Betancourt CE, Moncla A, Milili M et al. Defective B-cell-negative selection and terminal differentiation in the ICF syndrome. Blood 103(7), 2683–2690 (2004).
  Medline CASGoogle Scholar
• 62 Ueda Y, Okano M, Williams C, Chen T, Georgopoulos K, Li E. Roles for Dnmt3b in mammalian development: a mouse model for the ICF syndrome. Development 133(6), 1183–1192 (2006).
  Medline CASGoogle Scholar
• 63 Heyn H, Vidal E, Sayols S et al. Whole-genome bisulfite DNA sequencing of a DNMT3B mutant patient. Epigenetics 7(6), 542–550 (2012).
  Medline CASGoogle Scholar
• 64 Matarazzo MR, Boyle S, D'esposito M, Bickmore WA. Chromosome territory reorganization in a human disease with altered DNA methylation. Proc. Natl Acad. Sci. USA 104(42), 16546–16551 (2007).
  Medline CASGoogle Scholar
• 65 Ono R, Taki T, Taketani T, Taniwaki M, Kobayashi H, Hayashi Y. LCX, leukemia-associated protein with a CXXC domain, is fused to MLL in acute myeloid leukemia with trilineage dysplasia having t(10;11)(q22;q23). Cancer Res. 62(14), 4075–4080 (2002).
  Medline CASGoogle Scholar
• 66 Lorsbach RB, Moore J, Mathew S, Raimondi SC, Mukatira ST, Downing JR. TET1, a member of a novel protein family, is fused to MLL in acute myeloid leukemia containing the t(10;11)(q22;q23). Leukemia 17(3), 637–641 (2003).
  Medline CASGoogle Scholar
• 67 Thirman MJ, Gill HJ, Burnett RC et al. Rearrangement of the MLL gene in acute lymphoblastic and acute myeloid leukemias with 11q23 chromosomal translocations. N. Engl. J. Med. 329(13), 909–914 (1993).
  Medline CASGoogle Scholar
• 68 Harrison CJ, Cuneo A, Clark R et al. Ten novel 11q23 chromosomal partner sites. European 11q23 Workshop participants. Leukemia 12(5), 811–822 (1998).
  Medline CASGoogle Scholar
• 69 Aventin A, La Starza R, Martinez C et al. Involvement of MLL gene in a t(10;11)(q22;q23) and a t(8;11)(q24;q23) identified by fluorescence in situ hybridization. Cancer Genet. Cytogenet. 108(1), 48–52 (1999).
  Medline CASGoogle Scholar
• 70 Kim HJ, Cho HI, Kim EC et al. A study on 289 consecutive Korean patients with acute leukaemias revealed fluorescence in situ hybridization detects the MLL translocation without cytogenetic evidence both initially and during follow-up. Br. J. Haematol. 119(4), 930–939 (2002).
  Medline CASGoogle Scholar
• 71 Shih LY, Liang DC, Fu JF et al. Characterization of fusion partner genes in 114 patients with de novo acute myeloid leukemia and MLL rearrangement. Leukemia 20(2), 218–223 (2006).
  Medline CASGoogle Scholar
• 72 Burmeister T, Meyer C, Schwartz S et al. The MLL recombinome of adult CD10-negative B-cell precursor acute lymphoblastic leukemia: results from the GMALL study group. Blood 113(17), 4011–4015 (2009).
  Medline CASGoogle Scholar
• 73 Meyer C, Kowarz E, Hofmann J et al. New insights to the MLL recombinome of acute leukemias. Leukemia 23(8), 1490–1499 (2009).
  Medline CASGoogle Scholar
• 74 Lee SG, Cho SY, Kim MJ et al. Genomic breakpoints and clinical features of MLL-TET1 rearrangement in acute leukemias. Haematologica 98(4), e55–57 (2013).
  MedlineGoogle Scholar
• 75 Ittel A, Jeandidier E, Helias C et al. First description of the t(10;11)(q22;q23)/MLL-TET1 translocation in a T-cell lymphoblastic lymphoma, with subsequent lineage switch to acute myelomonocytic myeloid leukemia. Haematologica 98(12), e166–168 (2013).
  MedlineGoogle Scholar
• 76 Jin SG, Jiang Y, Qiu R et al. 5-Hydroxymethylcytosine is strongly depleted in human cancers but its levels do not correlate with IDH1 mutations. Cancer Res. 71(24), 7360–7365 (2011).
  Medline CASGoogle Scholar
• 77 Muller T, Gessi M, Waha A et al. Nuclear exclusion of TET1 is associated with loss of 5-hydroxymethylcytosine in IDH1 wild-type gliomas. Am. J. Pathol. 181(2), 675–683 (2012).
  MedlineGoogle Scholar
• 78 Yang H, Liu Y, Bai F et al. Tumor development is associated with decrease of TET gene expression and 5-methylcytosine hydroxylation. Oncogene 32(5), 663–669 (2013).
  Medline CASGoogle Scholar
• 79 Huang H, Jiang X, Li Z et al. TET1 plays an essential oncogenic role in MLL-rearranged leukemia. Proc. Natl Acad. Sci. USA 110(29), 11994–11999 (2013).
  Medline CASGoogle Scholar
• 80 Shih AH, Abdel-Wahab O, Patel JP, Levine RL. The role of mutations in epigenetic regulators in myeloid malignancies. Nat. Rev. Cancer 12(9), 599–612 (2012).
  Medline CASGoogle Scholar
• 81 Quivoron C, Couronne L, Della Valle V et al. TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. Cancer Cell 20(1), 25–38 (2011).
  Medline CASGoogle Scholar
• 82 Couronne L, Bastard C, Bernard OA. TET2 and DNMT3A mutations in human T-cell lymphoma. N. Engl. J. Med. 366(1), 95–96 (2012).
  Medline CASGoogle Scholar
• 83 Mariani CJ, Madzo J, Moen EL, Yesilkanal A, Godley LA. Alterations of 5-hydroxymethylcytosine in human cancers. Cancers 5(3), 786–814 (2013).
  Medline CASGoogle Scholar
• 84 Ko M, Huang Y, Jankowska AM et al. Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. Nature 468(7325), 839–843 (2010).
  Medline CASGoogle Scholar
• 85 Prensner JR, Chinnaiyan AM. Metabolism unhinged: IDH mutations in cancer. Nat. Med. 17(3), 291–293 (2011).
  Medline CASGoogle Scholar
• 86 Yamazaki J, Taby R, Vasanthakumar A et al. Effects of TET2 mutations on DNA methylation in chronic myelomonocytic leukemia. Epigenetics 7(2), 201–207 (2012).
  Medline CASGoogle Scholar
• 87 Ge L, Zhang RP, Wan F et al. TET2 plays an essential role in erythropoiesis by regulating lineage-specific genes via DNA oxidative demethylation in a zebrafish model. Mol. Cell Biol. 34(6), 989–1002 (2014).
  MedlineGoogle Scholar
• 88 Langemeijer SM, Kuiper RP, Berends M et al. Acquired mutations in TET2 are common in myelodysplastic syndromes. Nat. Genet. 41(7), 838–842 (2009).
  Medline CASGoogle Scholar
• 89 Seshagiri S, Stawiski EW, Durinck S et al. Recurrent R-spondin fusions in colon cancer. Nature 488(7413), 660–664 (2012).
  Medline CASGoogle Scholar
• 90 Amir RE, Van Den Veyver IB, Wan M, Tran CQ, Francke U, Zoghbi HY. Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. Nat. Genet. 23(2), 185–188 (1999).•• First report identifying MeCP2 mutations in Rett syndrome.
  Medline CASGoogle Scholar
• 91 RettBASE. http://mecp2.chw.edu.au.
  Google Scholar
• 92 Evans JC, Archer HL, Colley JP et al. Early onset seizures and Rett-like features associated with mutations in CDKL5. Eur. J. Hum. Genet. 13(10), 1113–1120 (2005).
  Medline CASGoogle Scholar
• 93 Philippe C, Amsallem D, Francannet C et al. Phenotypic variability in Rett syndrome associated with FOXG1 mutations in females. J. Med. Genet. 47(1), 59–65 (2010).
  Medline CASGoogle Scholar
• 94 Weaving LS, Williamson SL, Bennetts B et al. Effects of MECP2 mutation type, location and X-inactivation in modulating Rett syndrome phenotype. Am. J. Med. Genet. 118A(2), 103–114 (2003).
  MedlineGoogle Scholar
• 95 Skene PJ, Illingworth RS, Webb S et al. Neuronal MeCP2 is expressed at near histone-octamer levels and globally alters the chromatin state. Mol. Cell 37(4), 457–468 (2010).
  Medline CASGoogle Scholar
• 96 Calfa G, Percy AK, Pozzo-Miller L. Experimental models of Rett syndrome based on Mecp2 dysfunction. Exp. Biol. Med. 236(1), 3–19 (2011).
  CASGoogle Scholar
• 97 Guy J, Hendrich B, Holmes M, Martin JE, Bird A. A mouse Mecp2-null mutation causes neurological symptoms that mimic Rett syndrome. Nat. Genet. 27(3), 322–326 (2001).
  Medline CASGoogle Scholar
• 98 Chen RZ, Akbarian S, Tudor M, Jaenisch R. Deficiency of methyl-CpG binding protein-2 in CNS neurons results in a Rett-like phenotype in mice. Nat. Genet. 27(3), 327–331 (2001).
  Medline CASGoogle Scholar
• 99 Shahbazian M, Young J, Yuva-Paylor L et al. Mice with truncated MeCP2 recapitulate many Rett syndrome features and display hyperacetylation of histone H3. Neuron 35(2), 243–254 (2002).
  Medline CASGoogle Scholar
• 100 Pelka GJ, Watson CM, Radziewic T et al. Mecp2 deficiency is associated with learning and cognitive deficits and altered gene activity in the hippocampal region of mice. Brain 129(Pt 4), 887–898 (2006).
  MedlineGoogle Scholar
• 101 Jentarra GM, Olfers SL, Rice SG et al. Abnormalities of cell packing density and dendritic complexity in the MeCP2 A140V mouse model of Rett syndrome/X-linked mental retardation. BMC Neurosci. 11, 19 (2010).
  MedlineGoogle Scholar
• 102 Goffin D, Allen M, Zhang L et al. Rett syndrome mutation MeCP2 T158A disrupts DNA binding, protein stability and ERP responses. Nat. Neurosci. 15(2), 274–283 (2012).
  CASGoogle Scholar
• 103 Collins AL, Levenson JM, Vilaythong AP et al. Mild overexpression of MeCP2 causes a progressive neurological disorder in mice. Hum. Mol. Genet. 13(21), 2679–2689 (2004).
  Medline CASGoogle Scholar
• 104 Guy J, Gan J, Selfridge J, Cobb S, Bird A. Reversal of neurological defects in a mouse model of Rett syndrome. Science 315(5815), 1143–1147 (2007).• Demonstrated that the phenotype of MeCP2 mutant mice can be reversed by postnatal restoration of endogenous MeCP2 expression.
  Medline CASGoogle Scholar
• 105 Giacometti E, Luikenhuis S, Beard C, Jaenisch R. Partial rescue of MeCP2 deficiency by postnatal activation of MeCP2. Proc. Natl Acad. Sci. USA 104(6), 1931–1936 (2007).
  Medline CASGoogle Scholar
• 106 Luikenhuis S, Giacometti E, Beard CF, Jaenisch R. Expression of MeCP2 in postmitotic neurons rescues Rett syndrome in mice. Proc. Natl Acad. Sci. USA 101(16), 6033–6038 (2004).
  Medline CASGoogle Scholar
• 107 Jugloff DG, Vandamme K, Logan R, Visanji NP, Brotchie JM, Eubanks JH. Targeted delivery of an Mecp2 transgene to forebrain neurons improves the behavior of female Mecp2-deficient mice. Hum. Mol. Genet. 17(10), 1386–1396 (2008).
  Medline CASGoogle Scholar
• 108 Kishi N, Macklis JD. MECP2 is progressively expressed in post-migratory neurons and is involved in neuronal maturation rather than cell fate decisions. Mol. Cell Neurosci. 27(3), 306–321 (2004).
  Medline CASGoogle Scholar
• 109 Tsujimura K, Abematsu M, Kohyama J, Namihira M, Nakashima K. Neuronal differentiation of neural precursor cells is promoted by the methyl-CpG-binding protein MeCP2. Exp. Neurol. 219(1), 104–111 (2009).
  Medline CASGoogle Scholar
• 110 Samaco RC, Mandel-Brehm C, Chao HT et al. Loss of MeCP2 in aminergic neurons causes cell-autonomous defects in neurotransmitter synthesis and specific behavioral abnormalities. Proc. Natl Acad. Sci. USA 106(51), 21966–21971 (2009).
  Medline CASGoogle Scholar
• 111 Hutchinson AN, Deng JV, Aryal DK, Wetsel WC, West AE. Differential regulation of MeCP2 phosphorylation in the CNS by dopamine and serotonin. Neuropsychopharmacology 37(2), 321–337 (2012).
  Medline CASGoogle Scholar
• 112 Georgel PT, Horowitz-Scherer RA, Adkins N, Woodcock CL, Wade PA, Hansen JC. Chromatin compaction by human MeCP2. Assembly of novel secondary chromatin structures in the absence of DNA methylation. J. Biol. Chem. 278(34), 32181–32188 (2003).
  Medline CASGoogle Scholar
• 113 Young JI, Hong EP, Castle JC et al. Regulation of RNA splicing by the methylation-dependent transcriptional repressor methyl-CpG binding protein 2. Proc. Natl Acad. Sci. USA 102(49), 17551–17558 (2005).
  Medline CASGoogle Scholar
• 114 Agarwal N, Becker A, Jost KL et al. MeCP2 Rett mutations affect large scale chromatin organization. Hum. Mol. Genet. 20(21), 4187–4195 (2011).
  Medline CASGoogle Scholar
• 115 Chen WG, Chang Q, Lin Y et al. Derepression of BDNF transcription involves calcium-dependent phosphorylation of MeCP2. Science 302(5646), 885–889 (2003).
  Medline CASGoogle Scholar
• 116 Martinowich K, Hattori D, Wu H et al. DNA methylation-related chromatin remodeling in activity-dependent BDNF gene regulation. Science 302(5646), 890–893 (2003).
  Medline CASGoogle Scholar
• 117 Zhou Z, Hong EJ, Cohen S et al. Brain-specific phosphorylation of MeCP2 regulates activity-dependent Bdnf transcription, dendritic growth, and spine maturation. Neuron 52(2), 255–269 (2006).
  Medline CASGoogle Scholar
• 118 Huang EJ, Reichardt LF. Neurotrophins: roles in neuronal development and function. Annu. Rev. Neurosci. 24, 677–736 (2001).
  Medline CASGoogle Scholar
• 119 El-Maarri O, Kareta MS, Mikeska T et al. A systematic search for DNA methyltransferase polymorphisms reveals a rare DNMT3L variant associated with subtelomeric hypomethylation. Hum. Mol. Genet. 18(10), 1755–1768 (2009).
  Medline CASGoogle Scholar